FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118833666> ?p ?o ?g. }

• W2118833666 abstract "Background: The effectiveness of two drugs, a Bruton9s Tyrosine Kinase inhibitor (BTKi: ibrutinib, PCI-32765) and a histone deacetylase inhibitor (HDACi: abexinostat, PCI-24781), was tested on a mouse model for non-small lung cancer (NSCLC). The Grg1 mouse model is a transgenic mouse line that overexpresses the Groucho-related gene (Grg1; TLE1 in humans) and develops tumors that resemble human non-small cell lung cancer. The tumors initiate at 1 month of age, progress to bronchioalveolar carcinoma, and continue to invasive adenocarcinoma by 8 months. Both abexinostat and ibrutinib have shown promising activity as single agents in hematologic malignancies in the clinic. In this model, abexinostat was tested to determine if it was effective against the Grg1/HDAC function in lung tumor growth. Ibrutinib was tested to determine if this drug had activity in vivo in solid tumors, and if so further determine the mechanism of action. Lastly, it was of interest to determine if the combination of these agents with possibly different mechanism would be more or less active compared to the single agents. Methods: Mice were treated with the drugs or vehicle in two therapeutic settings: early intervention, starting at 2 months or late intervention starting at 5 months of age. In both cases, the drugs were administered for 4 weeks, 5 days per week. Following treatment, mice were sacrificed and visible tumors on the lung surface were counted using a dissecting microscope. In addition, the left lobe was used for histological analysis and the number of tumors in 5 um sections over two levels of 100 um was determined. Tumors in the sections were counted and tumor diameter was measured. Results: In the 3 month old cohort (Figure 1), the average number of surface visible tumors in untreated mice was 5.9 (n=10), BTKi-treated mice was 2.6 (n=8), HDACi-treated mice was 2.9 (n=9), and BTKi and HDACi-treated mice was 1.4 (n=11). In the serial sections the number of tumors in untreated mice was 5, BTKi-treated was 2, HDACi-treated was 3 and BTKi and HDACi-treated was 3 (n=4 for all groups). In the 6 month old cohort, the average number per mice of surface visible tumors in untreated mice was variable and ranged from 0 to 13 tumors. However the number of large tumors (over 1 mm) was higher for the untreated mice than the treated mice (untreated: 1.0; BTKi-treated: 0.2, HDACi-treated: 0.2, BTKi and HDACi treated: 0.2; n=5 for all groups). Pharmacodynamic analysis of the tumors showed histone acetylation in abexinostat-treated tumors, but did not reveal BTK expression or occupancy with a fluorescent-labeled probe. However, significant differences were observed in immune-cell infiltration in the large tumors. While the large control tumors exhibited areas of necrotic cell death, HDACi-treated tumors had larger areas of tumor cell death as well as apoptotic macrophages whereas BTKi-treated tumors had few or no infiltrating live or apoptotic macrophages. Conclusions: NSCLC tumors and others solid tumors that over-express Grg1 may respond to treatment with HDACi or BTKi by different mechanisms; the combination is more active than either agent alone. Interestingly, even solid tumors, such as lung cancer, may respond to immunomodulatory drugs such as BTK inhibitors by modulating infiltrating immune cells. Abexinostat and ibrutinib thus may have potential as a combination for treating solid tumors. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):C243. Citation Format: Corrinne G. Lobe, Michael J. Allain, Wenyi Yang, Mint Sirisawad, Sriram Balasubramanian. Activity of BTK and HDAC inhibitors alone and in combination in a mouse model of non-small cell lung cancer. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr C243." @default.
• W2118833666 created "2016-06-24" @default.
• W2118833666 creator A5031044419 @default.
• W2118833666 creator A5049476928 @default.
• W2118833666 creator A5075217325 @default.
• W2118833666 creator A5079048180 @default.
• W2118833666 creator A5087648305 @default.
• W2118833666 date "2013-11-01" @default.
• W2118833666 modified "2023-10-14" @default.
• W2118833666 title "Abstract C243: Activity of BTK and HDAC inhibitors alone and in combination in a mouse model of non-small cell lung cancer." @default.
• W2118833666 doi "https://doi.org/10.1158/1535-7163.targ-13-c243" @default.
• W2118833666 hasPublicationYear "2013" @default.
• W2118833666 type Work @default.
• W2118833666 sameAs 2118833666 @default.
• W2118833666 citedByCount "1" @default.
• W2118833666 countsByYear W21188336662014 @default.
• W2118833666 crossrefType "proceedings-article" @default.
• W2118833666 hasAuthorship W2118833666A5031044419 @default.
• W2118833666 hasAuthorship W2118833666A5049476928 @default.
• W2118833666 hasAuthorship W2118833666A5075217325 @default.
• W2118833666 hasAuthorship W2118833666A5079048180 @default.
• W2118833666 hasAuthorship W2118833666A5087648305 @default.
• W2118833666 hasConcept C121608353 @default.
• W2118833666 hasConcept C126322002 @default.
• W2118833666 hasConcept C150903083 @default.
• W2118833666 hasConcept C170493617 @default.
• W2118833666 hasConcept C203014093 @default.
• W2118833666 hasConcept C207001950 @default.
• W2118833666 hasConcept C2776256026 @default.
• W2118833666 hasConcept C2777938653 @default.
• W2118833666 hasConcept C2778461978 @default.
• W2118833666 hasConcept C2779878957 @default.
• W2118833666 hasConcept C42362537 @default.
• W2118833666 hasConcept C502942594 @default.
• W2118833666 hasConcept C71924100 @default.
• W2118833666 hasConcept C86803240 @default.
• W2118833666 hasConcept C90059517 @default.
• W2118833666 hasConcept C98274493 @default.
• W2118833666 hasConceptScore W2118833666C121608353 @default.
• W2118833666 hasConceptScore W2118833666C126322002 @default.
• W2118833666 hasConceptScore W2118833666C150903083 @default.
• W2118833666 hasConceptScore W2118833666C170493617 @default.
• W2118833666 hasConceptScore W2118833666C203014093 @default.
• W2118833666 hasConceptScore W2118833666C207001950 @default.
• W2118833666 hasConceptScore W2118833666C2776256026 @default.
• W2118833666 hasConceptScore W2118833666C2777938653 @default.
• W2118833666 hasConceptScore W2118833666C2778461978 @default.
• W2118833666 hasConceptScore W2118833666C2779878957 @default.
• W2118833666 hasConceptScore W2118833666C42362537 @default.
• W2118833666 hasConceptScore W2118833666C502942594 @default.
• W2118833666 hasConceptScore W2118833666C71924100 @default.
• W2118833666 hasConceptScore W2118833666C86803240 @default.
• W2118833666 hasConceptScore W2118833666C90059517 @default.
• W2118833666 hasConceptScore W2118833666C98274493 @default.
• W2118833666 hasLocation W21188336661 @default.
• W2118833666 hasOpenAccess W2118833666 @default.
• W2118833666 hasPrimaryLocation W21188336661 @default.
• W2118833666 hasRelatedWork W11178864 @default.
• W2118833666 hasRelatedWork W11877123 @default.
• W2118833666 hasRelatedWork W12336852 @default.
• W2118833666 hasRelatedWork W14333088 @default.
• W2118833666 hasRelatedWork W15508361 @default.
• W2118833666 hasRelatedWork W17235185 @default.
• W2118833666 hasRelatedWork W2800146 @default.
• W2118833666 hasRelatedWork W6095507 @default.
• W2118833666 hasRelatedWork W6834028 @default.
• W2118833666 hasRelatedWork W9714991 @default.
• W2118833666 isParatext "false" @default.
• W2118833666 isRetracted "false" @default.
• W2118833666 magId "2118833666" @default.
• W2118833666 workType "article" @default.